John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events ...

Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, is scheduled to ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

A choppy stock market challenges investors to be patient and choose stocks carefully as the Q4 earnings season gets underway.

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today ...

NDAQ:BCRX) BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) ...